Clinical Trials
A clinical trial is a research study that tests how well new medical approaches work in people. Posts here follow CMT drug trials and their results. More in the glossary
-

·
CMT and Nutrition: What the Evidence Says
What the research says about diet, weight and CMT, why the supplements tested in CMT failed, which ones can hurt nerves, and the rare neuropathies where diet really is the treatment.
-

·
One Patient, One Drug—and a Possible Voucher
A drug made for a single patient is one of the most hopeful ideas in rare disease medicine. Drug companies hope to profit from them, if public funding and exclusive rights defray the costs of developing these drugs. People with rare diseases hope for a cure or better health outcomes. Can both interests align?
-

·
Faster, Less Predictable: What the FDA’s Turbulent Years Mean for CMT
The FDA has promised faster, more flexible rare disease approvals, but rejections, reversals, leadership churn, and pressure on research funding have made it less predictable. What that means for CMT patients and researchers.
-

·
Trial Watch #1: CMT Clinical Trials, October 2026
The first Trial Watch: the CMT drug trials underway or changed since 2024, from a Novartis CMT1A study recruiting only in Canada to a cancelled govorestat trial, with a plain-English note on each.
-

·
Three “Treatable CMT” Stories, and What the Market Taught Us
Three heavily publicized CMT treatments of 2019–2023 (govorestat, PXT3003, and Engensis) all ended without a CMT approval, and the way they ended says a lot about how drug development treats rare neuropathies.
-

·
Maybe it will work on CMT..?
It seems the new hope for VM202 as a CMT1A treatment is perhaps Helixmith’s latest attempt to find a market for an experimental product that has not panned out as hoped.
-

·
ACE-083 Trials Miss Their Functional Goals
Acceleron Pharma Inc’s ACE-083 drug trials “did not achieve statistically significant improvements in functional endpoints relative to placebo” with CMT patients, so it will no longer be developed.
-

·
Second Phase 3 Clinical Trial for CMT1A “Pleodrug”
In 2020, after the setback of a second phase 3 trial, Pharnext’s PXT3003 looked promising in people with CMT1A. Updated in 2026: that trial failed to improve disability, and Pharnext was liquidated.
-

·
The State of Research for Cures (2019)
The US-based CMTA (Charcot Marie Tooth Association) has a 12-year-old program called the Strategy to Accelerate Research (STAR) that is actively pursuing the causes and possible cures for CMT. STAR will cover nearly all CMT Type 1s and 2s, including types with as yet unidentified genetic causes.
